Incyte (MEX:INCY) Cyclically Adjusted Revenue per Share: MXN (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INCY Incyte Corp MEX:INCY
80 GF Score
Price MXN2,103.07
GF Value MXN1,523.17
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Incyte Cyclically Adjusted Revenue per Share?

Incyte MEX:INCY 80 Cyclically Adjusted Revenue per Share is MXN as of Jun. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 80/100 and a GF Value™ of MXN1,523.17 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Incyte's adjusted revenue per share for the three months ended in Jun. 2026 was MXN139.856. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN for the trailing ten years ended in Jun. 2026.

During the past 12 months, Incyte's average Cyclically Adjusted Revenue Growth Rate was 19.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 17.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 20.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 26.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Incyte was 36.80% per year. The lowest was -26.20% per year. And the median was 21.00% per year.

As of today (2026-09-22), Incyte's current stock price is MXN2103.07. Incyte's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN. Incyte's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Incyte was 72.80. The lowest was 4.21. And the median was 10.76.


Incyte  (MEX:INCY) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Incyte was 72.80. The lowest was 4.21. And the median was 10.76.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Incyte Cyclically Adjusted Revenue per Share Related Terms


Incyte Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Incyte's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Cyclically Adjusted Revenue per Share Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Incyte Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MEX:INCY vs ROIV, BNTX, INSM: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Incyte's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Incyte's Cyclically Adjusted PS Ratio falls into.


MEX:INCY
80GF Score
Incyte Corp MEX:INCY
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Incyte's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=139.856/333.9520*333.9520
=139.856

Current CPI (Jun. 2026) = 333.9520.

Incyte Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 26.018 241.428 35.989
201612 33.189 241.432 45.907
201703 39.935 243.801 54.702
201706 29.519 244.955 40.244
201709 32.002 246.819 43.299
201712 39.879 246.524 54.022
201803 33.827 249.554 45.267
201806 47.046 251.989 62.348
201809 39.523 252.439 52.285
201812 48.485 251.233 64.449
201903 44.042 254.202 57.859
201906 46.606 256.143 60.764
201909 49.212 256.759 64.007
201912 51.043 256.974 66.333
202003 52.584 258.115 68.034
202006 72.813 257.797 94.322
202009 62.705 260.280 80.454
202012 73.359 260.474 94.053
202103 55.484 264.877 69.953
202106 63.579 271.696 78.147
202109 73.272 274.310 89.203
202112 80.683 278.802 96.643
202203 67.438 287.504 78.333
202206 81.709 296.311 92.089
202209 74.348 296.808 83.652
202212 81.149 296.797 91.308
202303 66.880 301.836 73.996
202306 74.877 305.109 81.955
202309 69.345 307.789 75.240
202312 78.709 306.746 85.690
202403 65.878 312.332 70.438
202406 82.489 314.175 87.682
202409 109.987 315.301 116.493
202412 119.980 315.605 126.955
202503 108.425 319.799 113.223
202506 119.422 322.561 123.639
202509 126.354 324.800 129.914
202512 134.685 324.054 138.799
202603 108.051 330.213 109.274
202606 139.856 333.952 139.856

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN mean?
Incyte (MEX:INCY) has a Cyclically Adjusted Revenue per Share of MXN as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Incyte and its competitors.
Is Incyte's Cyclically Adjusted Revenue per Share too high?
Incyte's current Cyclically Adjusted Revenue per Share is MXN. Overall, Incyte has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Cyclically Adjusted Revenue per Share compare to ROIV and BNTX?
Incyte's Cyclically Adjusted Revenue per Share of MXN can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Incyte and its competitors. Incyte's current Cyclically Adjusted Revenue per Share is MXN. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN1,523.17, compared to a current price of MXN2,103.07 — trading 38.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN. Incyte's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Cyclically Adjusted Revenue per Share is MXN as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN2,103.07 is trading 38.1% above its estimated GF Value™ of MXN1,523.17. GuruFocus considers Incyte to be Significantly Overvalued.

Key valuation signals for MEX:INCY:

  • Cyclically Adjusted Revenue per Share: MXN
  • GF Value™: MXN1,523.17 vs. price of MXN2,103.07 (38.1% above fair value)
  • GF Score™: 80/100 with 3 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
80GF Score

Get the complete analysis for MEX:INCY

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,103.07
Price
MXN1,523.17
GF Value